IMMUNOENHANCING ANTIGEN RE-ENGINEERING PLATFORM FOR VACCINES & IMMUNOTHERAPIES DEVELOPMENT
IMX313 is a short DNA sequence fused
to the antigen gene. When the recombinant antigen is expressed as a protein, it spontaneously forms a heptamer, which makes it more visible to the immune system, and highly increases both B & T cell immune responses against the original antigen.
IMX313 is compatible with subunit, DNA and viral
vectors delivery systems, but also synergistic with conventional adjuvant technologies.
IMX313 is a proprietary technology of IMAXIO, wich generates IP for recombinant antigens developed on the platofrm.
PROOFS OF CONCEPT
PIPELINE & COLLABORATIONS
In order to pursue
the development of its proprietary technology IMX313, IMAXIO is searching for
new collaborations to develop vaccines & immunotherapies in addtional indications, and is looking in particular for partners who have know-how on antigens with a lack of immunogenicity. Please, feel free to contact us for more information.
Cell Responses Induced by Adenoviral Vectored Vaccines Can Be
Adjuvanted by Fusion of Antigen to the Oligomerization Domain of
C4b-Binding Protein. Emily K. Forbes, Simone C. de
Cassan, David Llewellyn, Sumi Biswas, Anna L. Goodman, Matthew G.
Cottingham, Carole A. Long, Richard J. Pleass, Adrian V. S. Hill, Fergal
Hill, Simon J. Draper. PLoS ONE. 2012 September;7(9):e44943.
of the Mycobacterium tuberculosis antigen 85A to an oligomerization
domain enhances its immunogenicity in both mice and non-human primates.
Spencer AJ, Hill F, Honeycutt JD, Cottingham MG, Bregu M, Rollier CS,
Furze J, Draper SJ, Søgaard KC, Gilbert SC, Wyllie DH, Hill AVS. PLoS
ONE. 2012 March;7(3):